drugset / Trial / NCT07043608
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
NaSingle-groupOpen-labelTreatment
Summary
This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) therapy in the adjuvant or first-line metastatic setting.
Timeline
- Start
- 2026-05-30
- Primary completion
- 2029-02-28
- Completion
- 2030-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanzalintinib | Small molecule | 100 mg | Oral |
| Background | Denosumab | Monoclonal antibody | — | Intravenous |
| Background | Ibandronate | Other / unclassified | — | Intravenous |
| Background | Zoledronic acid | Other / unclassified | — | Intravenous |